Revealing role of epigenetic modifiers and DNA oxidation in cell-autonomous regulation of Cancer stem cells

Table 1 Patient demographics

Patients	Age (Yrs)	Stage (Diagnosis)	Hormone Status	Treatment
1	40	3	Her2+ ER-	Pertuzumab, Trastuzumad Docetaxel, carboplatin
2	75	3a	Her2- ER+	no treatment
3	50	4/Relapse	Her2- ER-	Abraxane, Gemcytabine
4	65	2a	Her2+ ER+	Pertuzumab, Transtuzumab*
5	64	4/relapse	Her2- ER-	Sacituzumab, Govitecan
6	89	2a	Her2- ER+	Exemestane
7	67	4/relapse	Her2- ER+ (minimal)	Sacituzumab, Govitecan
8	55	3a	Her2- ER+	Anastrozole **
9***	64	2	Her2+ ER+	Pertuzumab, trastuzumab, carboplatin, docetaxel
10***	45	4	ER- Her2-	Adriamycin, Cyclophosphamide

*Post-treatment (ended 6/23), followed by endocrine therapy (Letrozol). At relapse, treated with Docetaxel and Carboplatin. Due to low tolerance, switched to listed treatment (Patient 4)
** Patient was treated between July 2020–November 2020. This followed surgery. At blood draw, patient was on endocrine therapy with Anastrozole. Currently no active disease
***Patients 9 and 10 blood samples were analyzed with in vitro studies (Table 3)

ISSN: 1478-811X